Cited by 56Gut microbiota and healthOral microbiology and periodontitis researchAdipokines, Inflammation, and Metabolic Diseases

Personalized microbiome‐based approaches to metabolic syndrome management and prevention: 使用基于微生物的个体化治疗方法来管理与预防代谢综合征

Shapiro, Hagit, Suez, Jotham, Elinav, Eran·2017·Journal of Diabetes

Abstract

Personalized or precision medicine is a novel clinical approach targeted to the individual patient and based on integration of clinical, genetic, and environmental factors that define a patient uniquely from other individuals featuring similar clinical symptoms. Such a personalized medicine approach is increasingly applied for diagnosis, clinical stratification, and treatment of metabolic syndrome (MetS)-associated risks and diseases, including obesity, type 2 diabetes, non-alcoholic fatty liver disease, and their complications. One emerging factor that governs MetS manifestations is the microbiome, the composition, function, growth dynamics, associated metabolite profile and diverse effects of which on host immune and metabolic systems can all significantly affect metabolic homeostasis. Interindividual differences in microbiome composition and function, as well as personal variations in microbial-derived products, pave the way towards microbiome-based personalized medicine in treating MetS-related diseases.

Integrity signals

Registry

Crossref · 10.1111/1753-0407.12501

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Shapiro, H., Suez, J., & Elinav, E.
Affiliations
Weizmann Institute of Science (IL)
Corresponding author
Elinav, Eran
Venue
Journal of Diabetes
Publisher
Wiley
Published
2017-02-02
Volume
9
Issue
3
Pages
226-236
ISSN
  • 1753-0393 (ISSN-L)
  • 1753-0407
OpenAlex
W2542071099
Cited by
56
References
21
Citations by year
2026: 6 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 12 · 2019: 6 · 2018: 6 · 2017: 5
FWCI
0.77
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
Keywords
metabolic syndrome, gut microbiota, personalized medicine, precision medicine, obesity, type 2 diabetes, non-alcoholic fatty liver disease, microbiota-based therapy, microbial metabolites, host-microbe interactions, metabolic homeostasis
MeSH terms
Gastrointestinal Microbiome, Diabetes Mellitus, Type 2, Feces, Humans, Obesity, Probiotics, Metabolic Syndrome, Prebiotics, Precision Medicine, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review